Connect with us

Company News

ENDRA Life Sciences reports Q1 2024 financial results

ENDRA Life Sciences Inc. reported financial results for the three months ended March 31, 2024 and provided a business update.

First quarter 2024 financial results
Operating expenses in the first quarter of 2024 were $2.8 million, compared with $2.9 million in the first quarter in 2023. The decrease was mainly due to lower research and development expenses.

Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.

Cash and cash equivalents were $1.1 million as of March 31, 2024.
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!